Write News

Jio IPO vs Paras Healthcare IPO: Which Has the Higher GMP and Listing Gain Potential?

Posted on 19th Oct 2026 02:18 pm by rohit kumar

The primary market is set for a relatively quieter week, with two mainboard initial public offerings (IPOs)—Jio Platforms and Paras Healthcare—scheduled to open for subscription from October 21 to October 23, 2026. Both issues are expected to attract investor attention, with grey market premiums (GMPs) indicating potential listing gains.

 

The upcoming IPO activity comes during a shortened trading week. The Indian stock market will remain closed on Tuesday, October 20, on account of Dussehra. The two IPOs will open on Wednesday and remain available for subscription until Friday.

 

Jio Platforms, the digital and telecom business backed by Reliance Industries, has set its price band at ₹1,065–₹1,119 per share. Paras Healthcare, a hospital operator, has fixed its price band at ₹660–₹693 per share.

 

Based on the GMP figures cited in the available market updates, Jio Platforms is indicating a higher potential listing premium than Paras Healthcare. However, grey market quotes are unofficial and can change quickly; they should not be treated as a guarantee of listing-day returns.

 

Jio Platforms IPO: Dates, Price Band and Lot Size

 

Jio Platforms' IPO is scheduled to open on October 21 and close on October 23, 2026. The company has fixed the price band at ₹1,065–₹1,119 per equity share, with a lot size of 12 shares.

 

Here are the key details of the Jio Platforms IPO:

 

IPO opening date: October 21, 2026

 

IPO closing date: October 23, 2026

 

Price band: ₹1,065–₹1,119 per share

 

Lot size: 12 shares

 

Minimum investment: ₹12,780 at the lower price band and ₹13,428 at the upper price band

 

Issue size: Approximately ₹30,213 crore, according to the reported offer details

 

Jio Platforms operates in telecom and digital services, including mobile connectivity, broadband and other technology-led offerings. The IPO has drawn attention because of the company's scale and its position within the Reliance Industries group.

 

The issue will give public-market investors an opportunity to participate in the business, although prospective investors should review the offer documents, valuation and associated risks before applying.

 

Jio Platforms IPO GMP: What Are the Potential Listing Gains?

 

According to the GMP figure cited in the supplied market update, the grey market premium for Jio Platforms stands at ₹237 per share. Based on the upper end of the issue price band, this implies an indicative listing price of ₹1,356 per share.

 

The calculation is as follows:

 

Upper price band: ₹1,119

 

Reported GMP: ₹237

 

Indicative listing price: ₹1,356

 

Implied premium: Approximately 21.18%

 

At the upper price band, a 12-share lot would cost ₹13,428. If the share were to list at the indicative price of ₹1,356, the lot would be valued at ₹16,272, implying a paper gain of ₹2,844 before charges and taxes.

 

These figures are estimates based on the reported GMP, not assured returns. GMP is based on unofficial grey-market activity, and the actual listing price may be materially different.

 

Paras Healthcare IPO: Dates, Price Band and Lot Size

 

Paras Healthcare is the second mainboard IPO scheduled to open next week. The company operates in the healthcare sector and has set its IPO price band at ₹660–₹693 per share.

 

The issue will open on October 21 and close on October 23, 2026. Its lot size is 21 shares.

 

Key details of the Paras Healthcare IPO include:

 

IPO opening date: October 21, 2026

 

IPO closing date: October 23, 2026

 

Price band: ₹660–₹693 per share

 

Lot size: 21 shares

 

Minimum investment: ₹13,860 at the lower price band and ₹14,553 at the upper price band

 

Issue size: Approximately ₹1,450 crore

 

Paras Healthcare's public issue is expected to draw interest from investors tracking the hospital and healthcare sector. Before applying, investors should examine the company's financial performance, debt position, expansion plans, valuation and the risks outlined in its offer documents.

 

Paras Healthcare IPO GMP: Estimated Listing Premium

 

The supplied market update cites a grey market premium of ₹96 per share for Paras Healthcare. Using the upper price band of ₹693, this implies an indicative listing price of ₹789.

 

The estimated figures are:

 

Upper price band: ₹693

 

Reported GMP: ₹96

 

Indicative listing price: ₹789

 

Implied premium: Approximately 13.85%

 

At the upper price band, one lot of 21 shares would require an investment of ₹14,553. If the shares were to list at the indicative price of ₹789, the lot would be valued at ₹16,569, implying a paper gain of ₹2,016 before charges and taxes.

 

As with Jio Platforms, the estimate is based on an unofficial GMP quote. The premium can rise or fall before listing, and the actual market price may differ from the implied price.

 

Which IPO Shows Higher Potential Listing Gains?

 

Based on the GMP figures cited above, Jio Platforms has the higher implied listing premium at approximately 21.18%, compared with around 13.85% for Paras Healthcare. On those figures alone, Jio Platforms shows the stronger grey-market indication.

 

However, GMP should not be the only factor in an IPO investment decision. It is unofficial, can fluctuate sharply and may not accurately predict the actual listing price. Investor demand, broader market conditions, valuation, company financials and the final subscription response can all affect listing performance.

 

Investors should also distinguish between the percentage return implied by GMP and the actual profit they may receive after listing. Brokerage charges, taxes and price movements after listing can affect realised returns.

 

What Should Investors Check Before Applying?

 

Before subscribing to either IPO, investors should review the red herring prospectus and other official disclosures. Key factors include the company's financial performance, valuation compared with listed peers, use of issue proceeds, business risks and the proportion of the offer comprising fresh shares versus an offer for sale.

 

The issue price and GMP alone do not establish whether an IPO is suitable for an individual investor. The decision should reflect investment goals, risk tolerance and the ability to withstand potential losses.

1 0 Tweet